|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Wyeth_Pharmaceuticals
gptkb:Ribavirin
gptkb:ribavirin
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:peginterferon
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
autoimmune hepatitis
decompensated liver disease
hypersensitivity to ribavirin
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
24 to 48 weeks
|
|
gptkbp:effective_date
|
gptkb:1998
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
oral capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rebetol
|
|
gptkbp:indication
|
chronic hepatitis C
|
|
gptkbp:ingredients
|
gptkb:ribavirin
|
|
gptkbp:interacts_with
|
gptkb:didanosine
gptkb:lamivudine
gptkb:stavudine
gptkb:zidovudine
antacids
|
|
gptkbp:is_atype_of
|
J05 A B02
|
|
gptkbp:is_monitored_by
|
blood counts
|
|
gptkbp:is_used_for
|
treating hepatitis C
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Merck_&_Co.
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
nucleoside analogue
|
|
gptkbp:related_to
|
HCV treatment
|
|
gptkbp:side_effect
|
gptkb:historical_event
gptkb:fandom
fatigue
headache
muscle pain
nausea
weight loss
cough
fever
chest pain
irritability
rash
hearing loss
joint pain
dry skin
insomnia
hemolytic anemia
thrombocytopenia
hypotension
palpitations
gout
pancreatitis
neutropenia
vision changes
dyspnea
hyperuricemia
|
|
gptkbp:social_structure
|
C15 H18 N6 O5 P
|
|
gptkbp:traded_on
|
gptkb:Rebetol
|
|
gptkbp:treatment
|
with interferon
|
|
gptkbp:type_of_care
|
important for efficacy
|